Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

APRE

Aprea Therapeutics Inc

Nov 08 • 04:00PM ET

3.55

Dollar change -0.43
Percentage change -10.80	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD VRTX AMGN BIIB REGN NBIX INCY

| Held by: VTI VXF DFAT DFAC

Index	-	P/E	-	EPS (ttm)	-2.81	Insider Own	12.45%	Shs Outstand	5.43M	Perf Week	-9.44%
Market Cap	17.21M	Forward P/E	-	EPS next Y	-1.47	Insider Trans	6.37%	Shs Float	4.76M	Perf Month	39.76%
Income	-13.51M	PEG	-	EPS next Q	-0.67	Inst Own	42.62%	Short Float	0.32%	Perf Quarter	10.25%
Sales	1.31M	P/S	13.13	EPS this Y	36.29%	Inst Trans	81.11%	Short Ratio	0.72	Perf Half Y	-36.49%
Book/sh	4.04	P/B	0.88	EPS next Y	41.59%	ROA	-51.30%	Short Interest	0.02M	Perf Year	-11.25%
Cash/sh	5.42	P/C	0.66	EPS next 5Y	-	ROE	-60.22%	52W Range	2.15 - 8.85	Perf YTD	-24.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.41%	ROI	-58.08%	52W High	-59.87%	Beta	0.97
Dividend TTM	-	Quick Ratio	7.28	Sales past 5Y	0.00%	Gross Margin	98.33%	52W Low	65.11%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	7.28	EPS Y/Y TTM	86.90%	Oper. Margin	-1126.65%	RSI (14)	46.52	Volatility	9.55% 12.57%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	130.31%	Profit Margin	-1030.42%	Recom	1.00	Target Price	15.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	25.75%	Payout	-	Rel Volume	2.70	Prev Close	3.98
Sales Surprise	57.60%	EPS Surprise	10.66%	Sales Q/Q	11.00%	Earnings	Nov 07 BMO	Avg Volume	21.17K	Price	3.55
SMA20	-9.13%	SMA50	6.13%	SMA200	-24.31%	Trades		Volume	57,124	Change	-10.80%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy	$37
Sep-29-20	Resumed	JP Morgan	Neutral	$25
Jun-22-20	Initiated	H.C. Wainwright	Neutral	$30
Apr-21-20	Initiated	Robert W. Baird	Outperform	$45
Oct-28-19	Initiated	RBC Capital Mkts	Outperform	$33
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight	$23
Oct-28-19	Initiated	JP Morgan	Neutral	$23

Nov-07-24 09:20AM	Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:40AM	Aprea Therapeutics presents preliminary results on APR-1051 (TipRanks)
Oct-23-24 08:30AM	Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire) -6.70%
Oct-14-24 08:30AM	Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit (GlobeNewswire)
07:03PM	Loading…
Oct-10-24 07:03PM	Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc (GuruFocus.com)
08:30AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire)
Oct-09-24 08:30AM	Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development (GlobeNewswire)
Sep-25-24 08:00AM	Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +7.19%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-12-24 08:30AM	Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 (GlobeNewswire) +6.21%
Sep-09-24 05:15PM	UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:30AM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
09:45AM	Loading…
Aug-12-24 09:45AM	Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-21-24 08:00AM	Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 (GlobeNewswire)
Jun-17-24 08:30AM	Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 (GlobeNewswire)
May-28-24 08:45AM	Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial (GlobeNewswire)
May-14-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.37%
08:30AM	Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-13-24 04:01PM	Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-24 09:15AM	Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-24 12:00PM	Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 (GlobeNewswire)
Mar-26-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:45AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-24 08:30AM	Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million (GlobeNewswire) -5.05%
08:29AM	Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers (GlobeNewswire)
04:45PM	Loading…
Mar-05-24 04:45PM	Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-06-24 08:01AM	Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor (GlobeNewswire) +11.97%
Jan-30-24 08:00AM	Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 (GlobeNewswire)
Jan-04-24 04:05PM	Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 (GlobeNewswire)
Nov-09-23 04:05PM	Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -5.19%
Oct-24-23 08:00AM	Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways (GlobeNewswire)
Oct-16-23 08:30AM	Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio (GlobeNewswire)
Sep-19-23 08:00AM	Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-11-23 08:00AM	Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors (GlobeNewswire)
Sep-06-23 04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 07:30AM	Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman (GlobeNewswire)
Aug-10-23 07:30AM	Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Jun-14-23 08:00AM	Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference (GlobeNewswire)
May-30-23 08:30AM	Aprea Therapeutics to Present at BIO International Convention (GlobeNewswire) +11.76%
May-15-23 04:05PM	Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire) -7.34% +6.20%
May-08-23 08:00AM	Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors (GlobeNewswire)
Apr-24-23 09:55AM	Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now (Zacks)
Apr-04-23 12:00PM	All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy (Zacks) -5.01%
Mar-30-23 04:05PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Mar-16-23 08:00AM	Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.26%
Mar-01-23 04:05PM	Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-27-23 04:05PM	Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Feb-22-23 08:41PM	Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.97%
04:05PM	Aprea Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-15-23 08:00AM	Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) (GlobeNewswire)
Feb-13-23 07:00AM	Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split (GlobeNewswire)
Jan-30-23 08:00AM	Aprea Therapeutics Appoints John Hamill as Chief Financial Officer (GlobeNewswire)
Jan-19-23 08:00AM	Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit (GlobeNewswire) -7.57%
Jan-12-23 09:56AM	Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies (Zacks)
Jan-11-23 08:00AM	Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors (GlobeNewswire) +11.99%
Nov-09-22 04:15PM	Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire) -10.88%
Sep-22-22 06:00PM	Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series (GlobeNewswire) -7.14%
Sep-08-22 08:00AM	Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:15PM	Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Aug-02-22 08:00AM	Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
May-19-22 06:30AM	The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal (American City Business Journals)
May-16-22 09:21AM	Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results (GlobeNewswire) -19.09%
Mar-15-22 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) +5.45% +14.37%
Mar-02-22 04:41AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-14-22 10:00AM	Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-06-22 08:00AM	Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 (GlobeNewswire)
Dec-14-21 08:00AM	Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.05%
Dec-13-21 08:00AM	Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.85%
Dec-10-21 10:30AM	Aprea (APRE) Reports FDA Removal of Clinical Hold on Study (Zacks)
Dec-09-21 12:30PM	FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies (Benzinga)
08:00AM	Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies (GlobeNewswire)
Nov-08-21 04:15PM	Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Nov-04-21 04:15PM	Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting (GlobeNewswire)
Sep-21-21 08:39AM	Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO (Benzinga)
07:01AM	18 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Sep-20-21 04:15PM	Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021 (GlobeNewswire)
08:42AM	Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock? (Zacks)
Sep-14-21 08:00AM	Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021 (GlobeNewswire)
Sep-03-21 07:21AM	Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares? (Simply Wall St.)
Aug-12-21 04:15PM	Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) -9.65%
06:00AM	Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program (GlobeNewswire)
Aug-05-21 05:00PM	Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs (GlobeNewswire)
Jul-21-21 08:00AM	Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML (GlobeNewswire) -5.52%
Jun-18-21 08:34AM	Implied Volatility Surging for Aprea (APRE) Stock Options (Zacks)
Jun-17-21 09:19AM	Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal (Zacks) -6.32%
Jun-16-21 09:24AM	Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients (Benzinga) +10.93%
08:00AM	Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint (GlobeNewswire)
Jun-13-21 12:45PM	Is Aprea Therapeutics, Inc. (APRE) A Good Stock To Buy? (Insider Monkey)
Jun-04-21 01:47AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Invest In Growth? (Simply Wall St.)
May-21-21 06:00AM	Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit (GlobeNewswire)
May-18-21 06:00AM	Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-06-21 04:15PM	Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Apr-16-21 09:15AM	Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021 (GlobeNewswire) +7.64%
Apr-08-21 11:15AM	Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +13.64%

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Duey Marc	Director	Oct 18 '24	Sale	4.58	6,462	29,583	233,651	Oct 25 05:42 PM
Gilad Oren	President/CEO	Oct 23 '24	Buy	3.92	500	1,958	333,395	Oct 24 08:30 AM
Duey Marc	Director	Oct 16 '24	Buy	4.39	30,000	131,700	240,113	Oct 17 08:30 AM
Gilad Oren	President/CEO	Oct 15 '24	Buy	2.90	250	725	332,895	Oct 16 08:31 AM
Duey Marc	Director	Oct 14 '24	Buy	2.58	190	490	210,113	Oct 16 08:30 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Oct 11 '24	Buy	2.46	50	123	19,368	Oct 16 08:30 AM
Seizinger Bernd R.	Director	Oct 11 '24	Buy	2.68	10,000	26,800	44,730	Oct 15 08:31 AM
Gilad Oren	President/CEO	Oct 14 '24	Buy	2.59	1,000	2,590	332,645	Oct 15 08:31 AM
Gilad Oren	President/CEO	Oct 10 '24	Buy	2.54	150	381	331,645	Oct 15 08:31 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Oct 10 '24	Buy	2.61	450	1,174	19,318	Oct 15 08:30 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Mar 13 '24	Buy	7.29	1,010	7,363	15,503	Mar 14 08:54 PM
Seizinger Bernd R.	Director	Mar 13 '24	Buy	7.29	6,860	50,009	33,685	Mar 14 08:53 PM
HENNEMAN JOHN B III	Director	Mar 13 '24	Buy	7.29	6,860	50,009	8,139	Mar 14 08:52 PM
Gilad Oren	President, CEO	Mar 13 '24	Buy	7.29	2,000	14,580	324,770	Mar 14 08:51 PM

Open in Screener

WINT

Windtree Therapeutics Inc

Nov 08 • 04:00PM ET

0.5850

Dollar change -0.0257
Percentage change -4.21	%

Healthcare • Biotechnology • USA • NASD

WINT Windtree Therapeutics Inc daily Stock Chart

Peers: AGIO INVA LPCN BLRX APTO ALT XOMA VRNA SCPH TFFP

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-29.88	Insider Own	5.23%	Shs Outstand	8.75M	Perf Week	-18.86%
Market Cap	4.90M	Forward P/E	-	EPS next Y	-	Insider Trans	1.25%	Shs Float	8.29M	Perf Month	-16.67%
Income	-11.38M	PEG	-	EPS next Q	-0.37	Inst Own	0.02%	Short Float	0.59%	Perf Quarter	-95.04%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	1.16%	Short Ratio	0.03	Perf Half Y	-85.73%
Book/sh	5.90	P/B	0.10	EPS next Y	-	ROA	-32.86%	Short Interest	0.05M	Perf Year	-96.81%
Cash/sh	0.21	P/C	2.72	EPS next 5Y	-	ROE	-103.25%	52W Range	0.60 - 22.36	Perf YTD	-95.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	66.05%	ROI	-100.21%	52W High	-97.38%	Beta	0.58
Dividend TTM	-	Quick Ratio	0.23	Sales past 5Y	-37.79%	Gross Margin	-	52W Low	-2.50%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	0.23	EPS Y/Y TTM	93.48%	Oper. Margin	0.00%	RSI (14)	26.76	Volatility	11.23% 14.36%
Employees	15	Debt/Eq	0.37	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	18.00
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	29.07%	Payout	-	Rel Volume	0.30	Prev Close	0.61
Sales Surprise	-	EPS Surprise	-157.83%	Sales Q/Q	-	Earnings	Aug 20 AMC	Avg Volume	1.65M	Price	0.58
SMA20	-24.80%	SMA50	-69.19%	SMA200	-88.31%	Trades		Volume	503,242	Change	-4.21%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-20	Initiated	Ladenburg Thalmann	Buy	$12.25

Nov-04-24 08:00AM	Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong (GlobeNewswire)
Oct-30-24 08:00AM	Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 (GlobeNewswire) -9.50%
Oct-24-24 08:26AM	Windtree Therapeutics completes national phase filings for istaroxime (TipRanks) -5.86%
Oct-23-24 08:00AM	Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World (GlobeNewswire)
Oct-21-24 08:00AM	Windtree To Present at the ThinkEquity Conference on October 30th (GlobeNewswire) +17.16%
08:15AM	Loading…
Oct-17-24 08:15AM	Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan (GlobeNewswire) +43.27%
Oct-09-24 08:00AM	Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design (GlobeNewswire) -18.48%
Sep-30-24 08:15AM	Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock (GlobeNewswire) -7.00%
Sep-26-24 04:05PM	Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET (GlobeNewswire) -6.55% -5.17%
Sep-25-24 08:15AM	Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire) -11.04%
Sep-04-24 08:00AM	Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Aug-20-24 04:05PM	Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates (GlobeNewswire) -6.06%
Aug-14-24 04:05PM	Windtree Announces New Additions and Changes to Its Board of Directors (GlobeNewswire) +9.11%
Jul-26-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +151.98%
Jul-25-24 08:00AM	Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data (GlobeNewswire) -10.60%
04:05PM	Loading…
Jul-22-24 04:05PM	Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock (GlobeNewswire)
May-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +7.73%
May-07-24 08:00AM	Windtree Therapeutics Regains Compliance with Nasdaq (GlobeNewswire) -9.74%
Apr-18-24 08:00AM	Windtree Therapeutics Announces Reverse Stock Split (GlobeNewswire) -15.32%
Apr-17-24 08:00AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
06:52AM	WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Apr-08-24 04:48PM	Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing (GlobeNewswire) -9.51%
Feb-01-24 08:00AM	Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research (GlobeNewswire)
Jan-31-24 08:00AM	Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives (GlobeNewswire) -6.60%
Jan-26-24 09:20AM	Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company (ACCESSWIRE)
Jan-25-24 08:30AM	Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company (GlobeNewswire)
Jan-18-24 09:00AM	Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China (ACCESSWIRE)
Jan-17-24 08:00AM	Windtree Therapeutics Announces License Agreement with Lees Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region (GlobeNewswire) -18.04%
Jan-02-24 04:05PM	Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator (GlobeNewswire) -10.61%
Dec-19-23 09:30AM	Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024 (ACCESSWIRE)
08:00AM	Loading…
Dec-18-23 08:00AM	Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Nov-16-23 08:00AM	Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent (GlobeNewswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 04:15PM	Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
Nov-08-23 08:00AM	Windtree to Present at the Sidoti Micro Cap Conference on November 16th (GlobeNewswire)
Oct-12-23 07:30AM	Windtree to Present at the ThinkEquity Conference on October 19th in New York City (GlobeNewswire) +18.42%
Oct-10-23 07:30AM	Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th (GlobeNewswire)
Oct-03-23 08:00AM	Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace) -7.02%
Aug-23-23 08:00AM	Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office (GlobeNewswire)
Aug-16-23 09:00AM	Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market (ACCESSWIRE)
Aug-07-23 04:05PM	Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire) +6.82%
Jul-25-23 09:25AM	Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure (ACCESSWIRE)
Jul-18-23 09:00AM	The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market (ACCESSWIRE)
Jul-14-23 09:00AM	Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That (ACCESSWIRE)
Jun-27-23 08:00AM	Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-12-23 08:00AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism (GlobeNewswire) -5.08%
Jun-05-23 08:00AM	Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones (GlobeNewswire) +8.63%
May-15-23 04:30PM	Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
May-11-23 12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey)
Apr-27-23 08:00AM	Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime (GlobeNewswire)
Apr-24-23 04:01PM	Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option (GlobeNewswire) -12.26%
Apr-20-23 08:30AM	Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering (GlobeNewswire) -57.68%
Apr-17-23 08:00AM	Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent (GlobeNewswire) +88.81%
Apr-03-23 07:35AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Mar-13-23 08:00AM	Windtree Regains Compliance with Nasdaq (GlobeNewswire)
Mar-06-23 08:00AM	Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime (GlobeNewswire)
Feb-28-23 08:00AM	Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure (GlobeNewswire)
Feb-27-23 08:00AM	Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -8.99%
Feb-24-23 08:00AM	Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office (GlobeNewswire) -15.85%
Feb-23-23 12:00PM	Windtree Therapeutics Announces Reverse Stock Split (GlobeNewswire) -34.40%
Jan-20-23 08:37AM	Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants (GlobeNewswire) -25.65%
Dec-05-22 07:30AM	Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance (GlobeNewswire) -5.43%
Nov-18-22 12:00PM	Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why (Zacks)
Nov-14-22 07:30AM	Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Oct-25-22 08:00AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent (GlobeNewswire)
Oct-06-22 06:50AM	Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-29-22 07:45AM	Windtree Therapeutics Stock Surges After Positive Istaroxime Data In Cardiogenic Shock (Benzinga) +6.15%
Sep-28-22 04:05PM	Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure (GlobeNewswire)
Sep-26-22 08:00AM	Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America (GlobeNewswire)
Sep-21-22 04:05PM	Windtree to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -6.13%
Sep-06-22 04:05PM	Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 02:59PM	Windtree Therapeutics out-licenses surfactant platform in a deal that could be worth nearly $80M (American City Business Journals) -28.14%
Aug-23-22 08:00AM	Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement (GlobeNewswire) +52.21%
Aug-11-22 04:05PM	Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Jun-29-22 08:00AM	Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value (GlobeNewswire)
May-23-22 10:12AM	Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid (GlobeNewswire) -11.25%
May-16-22 07:00AM	Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire) +6.82%
May-05-22 04:05PM	Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire) -7.75%
Apr-20-22 04:05PM	Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference (GlobeNewswire) -14.63%
07:00AM	Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Mar-31-22 04:05PM	Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference (GlobeNewswire)
03:26PM	Insiders who purchased Windtree Therapeutics, Inc. (NASDAQ:WINT) stock last year recover some losses which currently stand at US$47k (Simply Wall St.)
07:05AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates (GlobeNewswire)
Mar-22-22 01:47PM	Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress (Benzinga)
07:30AM	Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury (GlobeNewswire)
Mar-15-22 12:06PM	Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April (Benzinga)
07:00AM	Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Mar-10-22 08:00AM	Windtree to Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-01-22 02:36PM	Why Are Windtree Therapeutics Shares Trading Higher Today? (Benzinga) +15.93%
07:30AM	Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome (GlobeNewswire)
Dec-15-21 08:00AM	Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent (GlobeNewswire)
Nov-22-21 04:59PM	2 Moonshot Biotechs with 10x Potential (InvestorPlace) +11.26%
08:00AM	Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay Adding to Previously Reported Need for New Pharmacologic Innovation (GlobeNewswire)
Nov-10-21 04:05PM	Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates (GlobeNewswire)
Oct-26-21 10:33AM	3 Moonshot Stocks Insiders Are Buying and 2 That Are Getting Dumped (InvestorPlace)
08:51AM	2 Penny Stocks Insiders Are Buying (Benzinga)
Oct-25-21 07:30AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent (GlobeNewswire)
Oct-20-21 07:36AM	3 Penny Stocks Insiders Are Buying (Benzinga) +5.79%

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fraser Craig	President and CEO	Oct 08 '24	Buy	0.91	5,431	4,942	8,638	Oct 09 07:46 AM

APRE

Aprea Therapeutics Inc

WINT

Windtree Therapeutics Inc

Upgrade your FINVIZ experience